Clinical Trial Update: PT-CY With or Without Low-dose ATG for Lymphoid Malignancies Undergoing Allo-HSCT [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating PT-CY with or without low-dose ATG for lymphoid malignancies undergoing allogeneic hematopoietic stem cell transplantation; completed s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease
• Lymphoid Malignancies

Drugs mentioned

• ATG (anti-thymocyte globulin)
• PT-CY (post-transplant cyclophosphamide)

Snippet

Sponsor: Shanghai Jiao Tong University School of Medicine | Conditions: GVHD, Acute | Phase 2 | Status: COMPLETED